CN102282148B - 11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐 - Google Patents

11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐 Download PDF

Info

Publication number
CN102282148B
CN102282148B CN200980150325.5A CN200980150325A CN102282148B CN 102282148 B CN102282148 B CN 102282148B CN 200980150325 A CN200980150325 A CN 200980150325A CN 102282148 B CN102282148 B CN 102282148B
Authority
CN
China
Prior art keywords
salt
citrate
batch
hcl
dsc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980150325.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102282148A (zh
Inventor
B·迪莫克
李静霞
A·D·威廉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Therapeutics Europe SRL
Original Assignee
CTI BIOLOGICAL MEDICAL Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CTI BIOLOGICAL MEDICAL Inc filed Critical CTI BIOLOGICAL MEDICAL Inc
Publication of CN102282148A publication Critical patent/CN102282148A/zh
Application granted granted Critical
Publication of CN102282148B publication Critical patent/CN102282148B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C07D201/02—Preparation of lactams
    • C07D201/10—Preparation of lactams from cycloaliphatic compounds by simultaneous nitrosylation and rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
CN200980150325.5A 2008-12-11 2009-12-09 11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐 Active CN102282148B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12166808P 2008-12-11 2008-12-11
US61/121,668 2008-12-11
PCT/SG2009/000473 WO2010068181A1 (en) 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt

Publications (2)

Publication Number Publication Date
CN102282148A CN102282148A (zh) 2011-12-14
CN102282148B true CN102282148B (zh) 2014-12-24

Family

ID=41666397

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980150325.5A Active CN102282148B (zh) 2008-12-11 2009-12-09 11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐

Country Status (23)

Country Link
US (2) US8980873B2 (enExample)
EP (1) EP2376499B1 (enExample)
JP (1) JP5669748B2 (enExample)
KR (1) KR101729918B1 (enExample)
CN (1) CN102282148B (enExample)
AR (2) AR074724A1 (enExample)
AU (1) AU2009325147B2 (enExample)
BR (1) BRPI0922736B1 (enExample)
CA (1) CA2746058C (enExample)
DK (1) DK2376499T3 (enExample)
ES (1) ES2536558T3 (enExample)
HR (1) HRP20150428T1 (enExample)
IL (3) IL213418A0 (enExample)
MX (1) MX2011006206A (enExample)
MY (1) MY160005A (enExample)
NZ (1) NZ593223A (enExample)
PL (1) PL2376499T3 (enExample)
PT (1) PT2376499E (enExample)
RU (1) RU2527970C2 (enExample)
SG (1) SG171907A1 (enExample)
TW (1) TWI449705B (enExample)
WO (1) WO2010068181A1 (enExample)
ZA (1) ZA201104032B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011006206A (es) 2008-12-11 2011-07-20 S Bio Pte Ltd Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26- triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5 ,8,10,12(27),16,21,23-decaeno.
EP2376500B1 (en) * 2008-12-11 2015-02-25 Cti Biopharma Corp. 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene maleate salt
PL2837632T3 (pl) 2012-04-13 2017-01-31 Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. Pochodne triazabicyklo[3.2.1]oktanu użyteczne do leczenia chorób proliferacyjnych
CN105061467B (zh) * 2015-08-28 2017-08-25 苏州立新制药有限公司 一种帕克替尼的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058627A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Oxygen linked pyrimidine derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
HRP20030911A2 (en) * 2001-05-14 2004-02-29 Pfizer Prod Inc Citrate salt 5,8,14,-triazatetracyclo (10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>)-hexadeca-2 (11), 3,5,7,9-pentaene
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
KR20040066140A (ko) * 2001-11-29 2004-07-23 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]헥사데카-2(11),3,5,7,9-펜타엔의 숙신산염 및 그의 제약 조성물
MX2011006206A (es) 2008-12-11 2011-07-20 S Bio Pte Ltd Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26- triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5 ,8,10,12(27),16,21,23-decaeno.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058627A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Oxygen linked pyrimidine derivatives

Also Published As

Publication number Publication date
CN102282148A (zh) 2011-12-14
PL2376499T3 (pl) 2015-07-31
WO2010068181A8 (en) 2011-08-18
EP2376499A1 (en) 2011-10-19
BRPI0922736B1 (pt) 2022-02-22
CA2746058A1 (en) 2010-06-17
AR114133A2 (es) 2020-07-22
AU2009325147A1 (en) 2011-06-23
NZ593223A (en) 2013-08-30
SG171907A1 (en) 2011-07-28
ES2536558T3 (es) 2015-05-26
TW201028426A (en) 2010-08-01
BRPI0922736A2 (pt) 2017-10-31
RU2011126173A (ru) 2013-01-20
PT2376499E (pt) 2015-06-03
MX2011006206A (es) 2011-07-20
AR074724A1 (es) 2011-02-09
IL250310A0 (en) 2017-03-30
US20110294831A1 (en) 2011-12-01
IL289379A (en) 2022-02-01
AU2009325147B2 (en) 2014-08-14
CA2746058C (en) 2016-05-17
DK2376499T3 (en) 2015-05-04
JP5669748B2 (ja) 2015-02-12
IL213418A0 (en) 2011-07-31
WO2010068181A1 (en) 2010-06-17
HK1161877A1 (en) 2012-08-10
HRP20150428T1 (xx) 2015-06-19
JP2012511571A (ja) 2012-05-24
RU2527970C2 (ru) 2014-09-10
US9624242B2 (en) 2017-04-18
KR20110106344A (ko) 2011-09-28
KR101729918B1 (ko) 2017-04-25
ZA201104032B (en) 2012-08-29
US20150322084A1 (en) 2015-11-12
BRPI0922736A8 (pt) 2021-11-09
MY160005A (en) 2017-02-15
TWI449705B (zh) 2014-08-21
EP2376499B1 (en) 2015-02-25
US8980873B2 (en) 2015-03-17

Similar Documents

Publication Publication Date Title
EP3022209B1 (en) Dolutegravir potassium salt
WO2022258584A1 (en) New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
JP2023527412A (ja) プラルセチニブの固体形態
CN102282148B (zh) 11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐
WO2015085972A1 (en) NOVEL SALTS OF 3-(2-IMIDAZO[1,2-b]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-[4-[(4-METHYL- 1-PIPERAZINYL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL] BENZAMIDE
US8987243B2 (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-maleate salt
CN102762577B (zh) 9e-15-(2-吡咯烷-1-基-乙氧基)-7,12,25-三氧杂-19,21,24-三氮杂-四环[18.3.1.1(2,5).1(14,18)]二十六碳-1(24),2,4,9,14,16,18(26),20,22-壬烯柠檬酸盐
CN118388481A (zh) 用于制备fgfr抑制剂的方法
WO2013181251A9 (en) Crizotinib hydrochloride salt in crystalline
KR20250107260A (ko) 2-(4-(2-(7,8-디메틸-[1,2,4]트리아졸로[1,5-a] 피리딘-6-일)-3-이소프로필-1H-인돌-5-일)피페리딘-1-일)아세트아미드 염 및 그의 결정질 형태
HK1161877B (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
WO2016004911A1 (en) A cocrystal of ivabradine hydrochloride and (r)-mandelic acid and its pharmaceutical composition
HK1178159B (en) 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: CELL THERAPEUTICS EUROP S. R. L. (US)

Free format text: FORMER OWNER: S*

Effective date: 20130319

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130319

Address after: Washington State

Applicant after: Cell Therapeutics Europ S. R. L. (US)

Address before: Singapore Singapore

Applicant before: S. Bio Pte Ltd.

C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Washington State

Applicant after: CTI BIOLOGICAL MEDICAL INC.

Address before: Washington State

Applicant before: Cell Therapeutics Europ S. R. L. (US)

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: CELL THERAPEUTICS EUROP S. R. L. (US) TO: CTI BIOLOGICAL PHARMACEUTICAL CO., LTD.

C14 Grant of patent or utility model
GR01 Patent grant